Methods of treating viral infections using IL-21

Details Methods of treating viral infections using IL-21 Methods of treating viral infections using IL-21

2011-06-14

2011-06-14

Jiang, Dong (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S351000, C435S069700, C435S007200

Reexamination Certificate

active

07959908

ABSTRACT:
Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known antimicrobial or antiviral therapeutics.

REFERENCES:
patent: 6057128 (2000-05-01), Donaldson et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6605272 (2003-08-01), Novak et al.
patent: 6686178 (2004-02-01), Novak et al.
patent: 2004/0016010 (2004-01-01), Kasaian et al.
patent: 03/028630 (2003-04-01), None
patent: 03/082212 (2003-10-01), None
patent: 03/087320 (2003-10-01), None
patent: 2004/007682 (2004-01-01), None
U.S. Appl. No. 10/456,780, filed Jun. 6, 2003, Nelson et al.
U.S. Appl. No. 10/735,149, filed Dec. 12, 2003, Zamost et al.
U.S. Appl. No. 11/539,036, filed Oct. 5, 2006, Zamost et al.
U.S. Appl. No. 11/539,045, filed Oct. 5, 2006, Zamost et al.
U.S. Appl. No. 11/539,055, filed Oct. 5, 2006, Zamost et al.
U.S. Appl. No. 11/134,489, filed May 20, 2005, Kingsvogel et al.
U.S. Appl. No. 11/553,367, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,381, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,389, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,392, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/553,395, filed Oct. 26, 2006, Nelson et al.
U.S. Appl. No. 11/548,196, filed Oct. 10, 2006, Nelson et al.
U.S. Appl. No. 11/548,202, filed Oct. 10, 2006, Nelson et al.
U.S. Appl. No. 11/548,517, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,530, filed Oct, 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,538, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,554, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,567, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,574, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,585, filed Oct. 11, 2006, Nelson et al.
U.S. Appl. No. 11/548,877, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/548,946, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/548,963, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/548,969, filed Oct. 12, 2006, Nelson et al.
U.S. Appl. No. 11/539,479, filed Oct. 6, 2006, Kindsvogel et al.
U.S. Appl. No. 11/539,493, filed Oct. 6, 2006, Kindsvogel et al.
U.S. Appl. No. 11/539,511, filed Oct. 6, 2006, Kindsvogel et al.
U.S. Appl. No. 11/285,970, filed Nov. 23, 2005, Yee.
U.S. Appl. No. 10/659,684, filed Sep. 10, 2003, Novak et al.
U.S. Appl. No. 11/549,772, filed Oct. 16, 2006, Novak et al.
U.S. Appl. No. 11/551,807, filed Oct. 23, 2006, Novak et al.
U.S. Appl. No. 11/551,344, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/549,868, filed Oct. 16, 2006, Novak et al.
U.S. Appl. No. 11/551,356, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/551,362, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/551,368, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/551,811, filed Oct. 23, 2006, Novak et al.
U.S. Appl. No. 11/551,820, filed Oct. 23, 2006, Novak et al.
U.S. Appl. No. 10/787,442, filed Feb. 26, 2004, Novak et al.
U.S. Appl. No. 11/532,776, filed Sep. 18, 2006, Novak et al.
U.S. Appl. No. 11/551,127, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,136, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,139, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,144, filed Oct. 19, 2006, Novak et al.
U.S. Appl. No. 11/551,349, filed Oct. 20, 2006, Novak et al.
U.S. Appl. No. 11/563,928, filed Nov. 28, 2006, Sivakumar et al.
U.S. Appl. No. 11/564,001, filed Nov. 28, 2006, Sivakumar et al.
U.S. Appl. No. 11/346,580, filed Feb. 2, 2006, Novak et al.
Brandt et al., “Interleukin-21 inhibits dendritic cell activation and maturation,”Blood102(12):4090-8, 2003.
Cui et al., “Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice,”Gene Therapy12:160-168, 2005.
Strengell et al., “IL-21 Up-Regulates the Expression of Genes Associated with Innate Immunity and Th1 Response” J. Immunol. 3601-3605, 2002.
Eberl, “Differentiation of human γδ T cells towards distinct memory phenotypes,”Cellular Immunology218:1-6, 2002.
Eberl, “Accumulation of a potent γδ T-cell stimulator after deletion of thelytBgene inEscherichia coli,” Immunology106:200-211, 2002.
Witek, “Primary Macrophages Express IL-21R and Resond to IL-21 by Proliferating and Secreting Increased Levels of Cytokines and Chemokines,” P-2-12, 2002. Publisher Not Available.
1483966, Marra, WashU-HHMI Mouse EST Project, 1996.
Parrish-Novak et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,”Nature408:57-63, 2000.
Van Leeuwen et al., “Proliferation Requirements of Cytomegalovirus-Specific, Effector-Type Human CD8+ T Cells,”J. Immunol.5838-5843, 2002.
Fahey et al., “Status of immune-based therapy in HIV infection and AIDS,”Clin. Exp. Immunol.88:1-5, 1992.

Affiliated with

Also associated with

Rating

Methods of treating viral infections using IL-21 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating viral infections using IL-21, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating viral infections using IL-21 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2681129